Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.

Autor:	Yuan, Yuan, Yost, Susan E, Cui, Yujie, Ruel, Christopher, Murga, Mireya, Tang, Aileen, Martinez, Norma, Schmolze, Daniel, Waisman, James, Patel, Niki, Vora, Lalit, Tumyan, Lusine, Bozoghlanian, Mari, Stewart, Daphne, Frankel, Paul H
Předmět:	THERAPEUTIC use of monoclonal antibodies THERAPEUTIC use of antineoplastic agents DRUG efficacy COGNITION disorders CARBOPLATIN CLINICAL trials DIARRHEA STOMATITIS NEUROLOGICAL disorders PROTEIN kinase inhibitors METASTASIS ANTINEOPLASTIC agents NEUTROPENIA EXANTHEMA LYMPHOPENIA ANEMIA RESEARCH funding PACLITAXEL PROGRESSION-free survival FATIGUE (Physiology) BREAST tumors PATIENT safety OVERALL survival EVALUATION
Zdroj:	Oncologist; Jul2023, Vol. 28 Issue 7, pe498-e507, 10p, 1 Diagram, 4 Charts, 2 Graphs
Abstrakt:	Background This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple–negative breast cancer (mTNBC). Methods Eligibility criteria were mTNBC, RECIST 1.1 measurable disease, no prior use of platinum for metastatic disease (Arms A and B), and no prior exposure to immune checkpoint inhibitor (Arm C). Primary endpoints were safety and RP2D. Secondary endpoints were progression–free survival (PFS), response rate, and overall survival. Results RP2D for Arm A (n = 10) was ipatasertib 300 mg daily, carboplatin AUC2, and paclitaxel 80 mg m−2 days 1, 8, and 15 every 28 days. RP2D for Arm B (n = 12) was ipatasertib 400 mg daily and carboplatin AUC2 days 1, 8, and 15 every 28 days. RP2D for Arm C (n = 6) was likely ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m−2, twice a day, 7 days on 7 days off, and atezolizumab 840 mg days 1 and 15 every 28 days. The most common (≥10%) grade 3-4 AEs at RP2D for Arm A (N = 7 at RP2D) were neutropenia (29%), diarrhea (14%), oral mucositis (14%), and neuropathy (14%); Arm B had diarrhea (17%) and lymphopenia (25%); and Arm C had anemia, fatigue, cognitive disturbance, and maculopapular rash (17% each). Overall responses at RP2D were 29% Arm A, 25% Arm B, and 33% Arm C. PFS was 4.8, 3.9, and 8.2 months for patients on Arms A, B, and C, respectively. Conclusions Continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated. Further study is warranted in understanding the role of AKT inhibition in treatment of TNBCs. Trial registration NCT03853707. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu